ES2882956T3 - Método para proporcionar una terapia de pirfenidona a un paciente - Google Patents
Método para proporcionar una terapia de pirfenidona a un paciente Download PDFInfo
- Publication number
- ES2882956T3 ES2882956T3 ES16151564T ES16151564T ES2882956T3 ES 2882956 T3 ES2882956 T3 ES 2882956T3 ES 16151564 T ES16151564 T ES 16151564T ES 16151564 T ES16151564 T ES 16151564T ES 2882956 T3 ES2882956 T3 ES 2882956T3
- Authority
- ES
- Spain
- Prior art keywords
- pirfenidone
- day
- dose
- daily dose
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract description 196
- 229960003073 pirfenidone Drugs 0.000 title claims abstract description 193
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 20
- 238000000034 method Methods 0.000 title abstract description 9
- 239000007858 starting material Substances 0.000 claims abstract description 82
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 18
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 230000000737 periodic effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002411 adverse Effects 0.000 abstract description 11
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 230000002354 daily effect Effects 0.000 description 30
- 239000003999 initiator Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- -1 TGF-p1 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87059306P | 2006-12-18 | 2006-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2882956T3 true ES2882956T3 (es) | 2021-12-03 |
Family
ID=39259551
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16151564T Active ES2882956T3 (es) | 2006-12-18 | 2007-12-18 | Método para proporcionar una terapia de pirfenidona a un paciente |
| ES07865831T Active ES2395396T3 (es) | 2006-12-18 | 2007-12-18 | Método para proporcionar una terapia de pirfenidona a un paciente |
| ES11002040.1T Active ES2581844T3 (es) | 2006-12-18 | 2007-12-18 | Método para proporcionar una terapia de pirfenidona a un paciente |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07865831T Active ES2395396T3 (es) | 2006-12-18 | 2007-12-18 | Método para proporcionar una terapia de pirfenidona a un paciente |
| ES11002040.1T Active ES2581844T3 (es) | 2006-12-18 | 2007-12-18 | Método para proporcionar una terapia de pirfenidona a un paciente |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7767700B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2471534A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010513320A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE506060T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2667654C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1111699T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007014113D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2124945T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2882956T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006526A (cg-RX-API-DMAC7.html) |
| PL (2) | PL3053580T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2124945E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2124945T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008077068A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE506060T1 (de) | 2006-12-18 | 2011-05-15 | Intermune Inc | Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten |
| AU2012205256B2 (en) * | 2008-11-10 | 2015-05-28 | Intermune, Inc. | Pirfenidone Treatment for Patients with Atypical Liver Function |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| KR20110114684A (ko) * | 2009-01-26 | 2011-10-19 | 인터뮨, 인크. | 급성 심근 경색 및 연관된 질환을 치료하는 방법 |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| ES2913095T3 (es) | 2011-01-31 | 2022-05-31 | Avalyn Pharma Inc | Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| EP2968292A4 (en) | 2013-03-15 | 2016-11-23 | Intermune Inc | METHOD FOR IMPROVING MICROVASCULAR INTEGRITY |
| USD731783S1 (en) | 2014-04-16 | 2015-06-16 | Abbvie Inc. | Template for a prescription medicine container |
| USD731782S1 (en) | 2013-10-07 | 2015-06-16 | Abbvie Inc. | Template for a prescription medicine container |
| USD731171S1 (en) | 2013-10-07 | 2015-06-09 | Abbvie Inc. | Template for a prescription medicine container |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| ES2863700T3 (es) * | 2016-03-22 | 2021-10-11 | Mayo Found Medical Education & Res | Uso de inhibidores de ácido graso sintasa para tratar la fibrosis |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| ES3023840T3 (en) | 2017-07-31 | 2025-06-03 | Washington University St Louis | Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection |
| USD930974S1 (en) | 2018-03-22 | 2021-09-21 | Abbvie Inc. | Child-resistant medication container |
| USD930973S1 (en) | 2018-03-22 | 2021-09-21 | Abbvie Inc. | Child-resistant medication container |
| US11052021B2 (en) | 2018-03-22 | 2021-07-06 | Abbvie Inc. | Medicine container, method of assembling the container, and method of dispensing the medicine from the container |
| USD882243S1 (en) | 2018-03-26 | 2020-04-28 | Abbvie Inc. | Child-resistant medication container assembly |
| CA3107667A1 (en) * | 2018-07-27 | 2020-01-30 | Aimmune Therapeutics, Inc. | Oral immunotherapy unit dose dispensing systems and methods |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| GB2589635B (en) * | 2019-12-06 | 2021-12-01 | Merxin Ltd | Elongate form medicament carrier and medicament dispenser |
| CN117042738A (zh) * | 2021-03-17 | 2023-11-10 | 埃科特莱茵药品有限公司 | 药物剂量系统 |
| WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US695044A (en) * | 1901-12-28 | 1902-03-11 | Albert E Gibson | Non-refillable bottle. |
| SE9502370D0 (sv) | 1995-06-30 | 1995-06-30 | Astra Ab | Blister pack, especially for drugs, as well as method and device in manufacturing the same |
| US6956044B1 (en) * | 2000-02-21 | 2005-10-18 | Margolin Solomon B | Compositions and methods for treatment of epilepsy |
| US7867516B2 (en) * | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| EP1551369A4 (en) * | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
| US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| WO2004103296A2 (en) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| CA2525647A1 (en) * | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| US20070053877A1 (en) * | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| NZ565059A (en) * | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US20080003635A1 (en) * | 2006-06-12 | 2008-01-03 | Intermune, Inc. | High Throughput Collagen Synthesis Assay |
| JP5213852B2 (ja) * | 2006-06-15 | 2013-06-19 | シャンハイ ゲノミックス インク | 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用 |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| ATE506060T1 (de) * | 2006-12-18 | 2011-05-15 | Intermune Inc | Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| WO2008144720A2 (en) * | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
-
2007
- 2007-12-18 AT AT07865831T patent/ATE506060T1/de active
- 2007-12-18 PL PL16151564T patent/PL3053580T3/pl unknown
- 2007-12-18 EP EP12150201A patent/EP2471534A1/en not_active Withdrawn
- 2007-12-18 EP EP16151564.8A patent/EP3053580B1/en active Active
- 2007-12-18 US US11/959,338 patent/US7767700B2/en active Active
- 2007-12-18 PL PL07865831T patent/PL2124945T3/pl unknown
- 2007-12-18 MX MX2009006526A patent/MX2009006526A/es active IP Right Grant
- 2007-12-18 SI SI200730641T patent/SI2124945T1/sl unknown
- 2007-12-18 EP EP07865831A patent/EP2124945B1/en active Active
- 2007-12-18 DK DK07865831.7T patent/DK2124945T3/da active
- 2007-12-18 WO PCT/US2007/087988 patent/WO2008077068A1/en not_active Ceased
- 2007-12-18 JP JP2009541645A patent/JP2010513320A/ja active Pending
- 2007-12-18 ES ES16151564T patent/ES2882956T3/es active Active
- 2007-12-18 PT PT07865831T patent/PT2124945E/pt unknown
- 2007-12-18 DE DE602007014113T patent/DE602007014113D1/de active Active
- 2007-12-18 ES ES07865831T patent/ES2395396T3/es active Active
- 2007-12-18 EP EP11002040.1A patent/EP2338489B1/en not_active Revoked
- 2007-12-18 ES ES11002040.1T patent/ES2581844T3/es active Active
- 2007-12-18 CA CA2667654A patent/CA2667654C/en active Active
-
2009
- 2009-04-21 US US12/427,532 patent/US7696236B2/en active Active
-
2010
- 2010-07-07 US US12/831,944 patent/US8420674B2/en active Active
-
2011
- 2011-07-12 CY CY20111100674T patent/CY1111699T1/el unknown
-
2013
- 2013-04-11 US US13/861,099 patent/US20130220871A1/en not_active Abandoned
-
2016
- 2016-07-18 US US15/212,674 patent/US20160324842A1/en not_active Abandoned
-
2018
- 2018-01-18 US US15/874,590 patent/US20180140588A1/en not_active Abandoned
- 2018-09-07 US US16/125,299 patent/US20190000821A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,532 patent/US20190247380A1/en not_active Abandoned
- 2019-12-06 US US16/706,575 patent/US20200113884A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2882956T3 (es) | Método para proporcionar una terapia de pirfenidona a un paciente | |
| ES2182729T3 (es) | Envase de tiras. | |
| ES2525262T3 (es) | Sistema de apertura de un blíster médico | |
| US20020066691A1 (en) | Therapy pack | |
| US9408777B2 (en) | Blister package for patient compliance | |
| JP2010513320A5 (cg-RX-API-DMAC7.html) | ||
| KR20060038998A (ko) | 적정/복약이행 팩 | |
| CN101500578A (zh) | 用于全身抗癌治疗的计量剂量的以及安全和顺应性包装 | |
| US20040171992A1 (en) | Cream dispenser providing sequential dispensing means | |
| HK1227319A1 (en) | Method of providing pirfenidone therapy to a patient | |
| HK1172827A (en) | Method of providing pirfenidone therapy to a patient | |
| HK1133584B (en) | Method of providing pirfenidone therapy to a patient | |
| HK1153647B (en) | Method of providing pirfenidone therapy to a patient | |
| US6630149B1 (en) | Blister containing a transdermal therapeutic system and a single dose form of administration | |
| CN211461235U (zh) | 一种高血压患者专用药盒 | |
| WO2021014468A1 (en) | Blister package for improved patient compliance | |
| RU94457U1 (ru) | Упаковка суточной дозы лекарственных препаратов перорального применения для комплексной медикаментозной терапии (варианты) и упаковка лекарственных препаратов перорального применения для курса комплексной медикаментозной терапии | |
| ES1227862U (es) | Envase tipo blister para la administracion combinada de dos medicamentos en forma de pastillas o capsulas |